Retroperitoneal fibrosis secondary to non-urology carcinomas: a clinical and outcome analysis of 97 cases
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-018-1936-y
Abstract: PurposeAccumulated evidences have reminded us that since the prognosis of retroperitoneal fibrosis (RPF) secondary to non-urology carcinoma is poor it is essential to distinguish this condition from others. The objective of this study is to… read more here.
Keywords: rpf; carcinoma; non urology; secondary non ... See more keywords
Clinical Efficacy of Alternative TNF Inhibitor and Secukinumab Between Primary Non-Responder and Secondary Non-Responder of Prior TNF Inhibitor in Ankylosing Spondylitis.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac005
Abstract: OBJECTIVE To compare the drug retention times and clinical efficacy of alternative tumor necrosis factor inhibitors (TNFi) and secukinumab in primary and secondary non-responders with ankylosing spondylitis (AS). METHODS AS patients treated with biologics and… read more here.
Keywords: non; secondary non; non responder; clinical efficacy ... See more keywords
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac150
Abstract: OBJECTIVES Secondary inefficacy with infusion reactions and anti-drug antibodies (2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy and safety of obinutuzumab, a next-generation humanised type-2 anti-CD20… read more here.
Keywords: non response; response rituximab; secondary non; sle patients ... See more keywords